



SAFETY DATA SHEET

Revision date: 19-Jul-2016

Version: 1.1

Page 1 of 8

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND THE COMPANY/UNDERTAKING

Product Identifier

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)

Trade Name: Not established

Chemical Family: Not determined

Relevant Identified Uses of the Substance or Mixture and Uses Advised Against

Intended Use: Pharmaceutical product used as Antineoplastic

Details of the Supplier of the Safety Data Sheet

Hospira, A Pfizer Company
275 North Field Drive
Lake Forest, Illinois 60045
1-800-879-3477

Hospira UK Limited

Horizon

Honey Lane

Hurley

Maidenhead, SL6 6RJ

United Kingdom

Emergency telephone number:

CHEMTREC (24 hours): 1-800-424-9300

Contact E-Mail: pfizer-MSDS@pfizer.com

Emergency telephone number:

International CHEMTREC (24 hours): +1-703-527-3887

2. HAZARDS IDENTIFICATION

Classification of the Substance or Mixture

GHS - Classification

Germ Cell Mutagenicity: Category 1B

Reproductive Toxicity: Category 1B

Label Elements

Signal Word: Danger

Hazard Statements: H360D - May damage the unborn child

H340 - May cause genetic defects

Precautionary Statements:

P201 - Obtain special instructions before use

P281 - Use personal protective equipment as required

P308 + P313 - IF exposed or concerned: Get medical attention/advice

P405 - Store locked up

P501 - Dispose of contents/container in accordance with all local and national regulations

SAFETY DATA SHEET

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Revision date: 19-Jul-2016

Page 2 of 8

Version: 1.1



Other Hazards Note:

No data available

This document has been prepared in accordance with standards for workplace safety, which requires the inclusion of all known hazards of the product or its ingredients regardless of the potential risk. The precautionary statements and warning included may not apply in all cases. Your needs may vary depending upon the potential for exposure in your workplace.

3. COMPOSITION / INFORMATION ON INGREDIENTS

Hazardous

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Oxaliplatin	61825-94-3	Not Listed	Repr.1B (H360D) Muta.1B (H340)	0.5
SODIUM HYDROXIDE	1310-73-2	215-185-5	Skin Corr. 1A (H314)	<1

Ingredient	CAS Number	EU EINECS/ELINCS List	GHS Classification	%
Tartaric acid	87-69-4	201-766-0	Not Listed	*
Water for Injection	7732-18-5	231-791-2	Not Listed	*

Additional Information:

* Proprietary

Ingredient(s) indicated as hazardous have been assessed under standards for workplace safety. In accordance with 29 CFR 1910.1200, the exact percentage composition of this mixture has been withheld as a trade secret.

For the full text of the CLP/GHS abbreviations mentioned in this Section, see Section 16

4. FIRST AID MEASURES

Description of First Aid Measures

Eye Contact:

Flush with water while holding eyelids open for at least 15 minutes. Seek medical attention immediately.

Skin Contact:

Remove contaminated clothing. Flush area with large amounts of water. Use soap. Seek medical attention.

Ingestion:

Never give anything by mouth to an unconscious person. Wash out mouth with water. Do not induce vomiting unless directed by medical personnel. Seek medical attention immediately.

Inhalation:

Remove to fresh air and keep patient at rest. Seek medical attention immediately.

Most Important Symptoms and Effects, Both Acute and Delayed

Symptoms and Effects of Exposure:

For information on potential signs and symptoms of exposure, See Section 2 - Hazards Identification and/or Section 11 - Toxicological Information.

SAFETY DATA SHEET

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Revision date: 19-Jul-2016

Page 3 of 8

Version: 1.1

Medical Conditions: None known
Aggravated by Exposure:

Indication of the Immediate Medical Attention and Special Treatment Needed
Notes to Physician: None

5. FIRE FIGHTING MEASURES

Extinguishing Media: Extinguish fires with CO₂, extinguishing powder, foam, or water.

Special Hazards Arising from the Substance or Mixture

Hazardous Combustion Products: Formation of toxic gases is possible during heating or fire.

Fire / Explosion Hazards: Fine particles (such as mists) may fuel fires/explosions.

Advice for Fire-Fighters

During all fire fighting activities, wear appropriate protective equipment, including self-contained breathing apparatus.

6. ACCIDENTAL RELEASE MEASURES

Personal Precautions, Protective Equipment and Emergency Procedures

Personnel involved in clean-up should wear appropriate personal protective equipment (see Section 8). Minimize exposure.

Environmental Precautions

Place waste in an appropriately labeled, sealed container for disposal. Care should be taken to avoid environmental release.

Methods and Material for Containment and Cleaning Up

Measures for Cleaning / Collecting: Contain the source of spill if it is safe to do so. Collect spill with absorbent material. Clean spill area thoroughly.

Additional Consideration for Large Spills: Non-essential personnel should be evacuated from affected area. Report emergency situations immediately. Clean up operations should only be undertaken by trained personnel.

7. HANDLING AND STORAGE

Precautions for Safe Handling

Avoid breathing vapor or mist. Avoid contact with eyes, skin and clothing. When handling, use appropriate personal protective equipment (see Section 8). Wash hands and any exposed skin after removal of PPE. Releases to the environment should be avoided. Review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure or environmental releases. Potential points of process emissions of this material to the atmosphere should be controlled with dust collectors, HEPA filtration systems or other equivalent controls.

Conditions for Safe Storage, Including any Incompatibilities

Storage Conditions: Store as directed by product packaging.

Specific end use(s): Pharmaceutical product used as Antineoplastic

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Control Parameters

Refer to available public information for specific member state Occupational Exposure Limits.

SODIUM HYDROXIDE

ACGIH Ceiling Threshold Limit: 2 mg/m³
Australia PEAK 2 mg/m³

SAFETY DATA SHEET

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)

Revision date: 19-Jul-2016

Page 4 of 8

Version: 1.1

8. EXPOSURE CONTROLS / PERSONAL PROTECTION

Austria OEL - MAKs	2 mg/m ³
Bulgaria OEL - TWA	2.0 mg/m ³
Czech Republic OEL - TWA	1 mg/m ³
Estonia OEL - TWA	1 mg/m ³
France OEL - TWA	2 mg/m ³
Greece OEL - TWA	2 mg/m ³
Hungary OEL - TWA	2 mg/m ³
Japan - OELs - Ceilings	2 mg/m ³
Latvia OEL - TWA	0.5 mg/m ³
OSHA - Final PELs - TWAs:	2 mg/m ³
Poland OEL - TWA	0.5 mg/m ³
Slovakia OEL - TWA	2 mg/m ³
Slovenia OEL - TWA	2 mg/m ³
Sweden OEL - TWAs	1 mg/m ³
Switzerland OEL - TWAs	2 mg/m ³

Tartaric acid

Germany (DFG) - MAK	2 mg/m ³
---------------------	---------------------

The purpose of the Occupational Exposure Band (OEB) classification system is to separate substances into different Hazard categories when the available data are sufficient to do so, but inadequate to establish an Occupational Exposure Limit (OEL). The OEB given is based upon an analysis of all currently available data; as such, this value may be subject to revision when new information becomes available.

Oxaliplatin

Pfizer Occupational Exposure Band (OEB): OEB 4 (control exposure to the range of 1ug/m³ to <10ug/m³)

Exposure Controls

Engineering Controls:	Engineering controls should be used as the primary means to control exposures. General room ventilation is adequate unless the process generates dust, mist or fumes. Keep airborne contamination levels below the exposure limits listed above in this section.
Personal Protective Equipment:	Refer to applicable national standards and regulations in the selection and use of personal protective equipment (PPE).
Hands:	Impervious gloves are recommended if skin contact with drug product is possible and for bulk processing operations.
Eyes:	Wear safety glasses or goggles if eye contact is possible.
Skin:	Impervious protective clothing is recommended if skin contact with drug product is possible and for bulk processing operations.
Respiratory protection:	If airborne exposures are within or exceed the Occupational Exposure Band (OEB) range, wear an appropriate respirator with a protection factor sufficient to control exposures to the bottom of the OEB range.

9. PHYSICAL AND CHEMICAL PROPERTIES

Physical State:	Solution	Color:	No data available.
Odor:	Odorless	Odor Threshold:	No data available.
Molecular Formula:	Mixture	Molecular Weight:	Mixture
Solvent Solubility:	No data available		
Water Solubility:	No data available		
pH:	4.8-7		

SAFETY DATA SHEET

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Revision date: 19-Jul-2016

Page 5 of 8

Version: 1.1

9. PHYSICAL AND CHEMICAL PROPERTIES

Melting/Freezing Point (°C): No data available

Boiling Point (°C): 100

Partition Coefficient: (Method, pH, Endpoint, Value)

Oxaliplatin

No data available

Tartaric acid

No data available

Water for Injection

No data available

SODIUM HYDROXIDE

No data available

Decomposition Temperature (°C): No data available.

Evaporation Rate (Gram/s): No data available

Vapor Pressure (kPa): No data available

Vapor Density (g/ml): No data available

Relative Density: No data available

Viscosity: No data available

Flammability:

Autoignition Temperature (Solid) (°C): No data available

Flammability (Solids): No data available

Flash Point (Liquid) (°C): No data available

Upper Explosive Limits (Liquid) (% by Vol.): No data available

Lower Explosive Limits (Liquid) (% by Vol.): No data available

10. STABILITY AND REACTIVITY

Reactivity: No data available

Chemical Stability: Stable under normal conditions of use.

Possibility of Hazardous Reactions

Oxidizing Properties: No data available

Conditions to Avoid: Fine particles (such as mists) may fuel fires/explosions. As a precautionary measure, keep away from heat sources and electrostatic discharge.

Incompatible Materials: As a precautionary measure, keep away from strong oxidizers

Hazardous Decomposition Products: No data available

11. TOXICOLOGICAL INFORMATION

Information on Toxicological Effects

General Information: The information included in this section describes the potential hazards of the active ingredient
Short Term: Individuals sensitive to this chemical or other materials in its chemical class may develop allergic reactions. In the workplace, platinum compounds have been reported to cause allergic skin and respiratory reactions.

Long Term: the developing fetus. May cause effects on blood and blood forming organs Repeat-dose studies in animals have shown a potential to cause adverse effects on testes and

Known Clinical Effects: Adverse effects most commonly reported in clinical use include vomiting nausea diarrhea bone marrow suppression decreased red blood cell count (anemia) decreased white blood cells (leukopenia) decrease in platelets and red/white blood cells (pancytopenia) nervous system/brain toxicity (neurotoxicity) and skin and acute mucous membrane irritation

SAFETY DATA SHEET

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Revision date: 19-Jul-2016

Page 6 of 8

Version: 1.1

11. TOXICOLOGICAL INFORMATION

Acute Toxicity: (Species, Route, End Point, Dose)

Oxaliplatin

Rat Oral LD50 > 100 mg/kg

Rat IP LD 50 14.3mg/kg

Mouse Intraperitoneal LD 50 19.8mg/kg

Acute Toxicity Comments: A greater than symbol (>) indicates that the toxicity endpoint being tested was not achievable at the highest dose used in the test.

Irritation / Sensitization: (Study Type, Species, Severity)

Oxaliplatin

Eye Irritation (*In vitro*, BCOP) Irritant

Skin Irritation (*In vitro*, RhE) Negative

Reproduction & Developmental Toxicity: (Study Type, Species, Route, Dose, End Point, Effect(s))

Oxaliplatin

Fertility and Embryonic Development Rat No route specified 1 mg/kg/day NOAEL Fetotoxicity

Genetic Toxicity: (Study Type, Cell Type/Organism, Result)

Oxaliplatin

Bacterial Mutagenicity (Ames) *Salmonella* Negative

In Vitro Mammalian Cell Mutagenicity Mouse Lymphoma Positive

In Vitro Chromosome Aberration Human Lymphocytes Positive

In Vivo Micronucleus Mouse Bone Marrow Positive

Carcinogen Status: Not listed as a carcinogen by IARC, NTP or US OSHA.

12. ECOLOGICAL INFORMATION

Environmental Overview: The environmental characteristics of this material have not been fully evaluated. Releases to the environment should be avoided.

Toxicity: No data available

Persistence and Degradability: No data available

Bio-accumulative Potential: No data available

Mobility in Soil: No data available

SAFETY DATA SHEET

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Revision date: 19-Jul-2016

Page 7 of 8

Version: 1.1

13. DISPOSAL CONSIDERATIONS

Waste Treatment Methods: Dispose of waste in accordance with all applicable laws and regulations. Member State specific and Community specific provisions must be considered. Considering the relevant known environmental and human health hazards of the material, review and implement appropriate technical and procedural waste water and waste disposal measures to prevent occupational exposure and environmental release. It is recommended that waste minimization be practiced. The best available technology should be utilized to prevent environmental releases. This may include destructive techniques for waste and wastewater.

14. TRANSPORT INFORMATION

The following refers to all modes of transportation unless specified below.

Not regulated for transport under USDOT, EUADR, IATA, or IMDG regulations.

15. REGULATORY INFORMATION

Safety, Health and Environmental Regulations/Legislation Specific for the Substance or Mixture

Oxaliplatin

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 4
EU EINECS/ELINCS List	Not Listed

SODIUM HYDROXIDE

CERCLA/SARA 313 Emission reporting	Not Listed
CERCLA/SARA Hazardous Substances and their Reportable Quantities:	1000 lb 454 kg
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
Standard for the Uniform Scheduling for Drugs and Poisons:	Schedule 5 Schedule 6
EU EINECS/ELINCS List	215-185-5

Tartaric acid

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
EU EINECS/ELINCS List	201-766-0

SAFETY DATA SHEET

Material Name: Oxaliplatin Injection (Solution for Intravenous Use) (Hospira Inc.)
Revision date: 19-Jul-2016

Page 8 of 8

Version: 1.1

15. REGULATORY INFORMATION

Water for Injection

CERCLA/SARA 313 Emission reporting	Not Listed
California Proposition 65	Not Listed
Inventory - United States TSCA - Sect. 8(b)	Present
Australia (AICS):	Present
REACH - Annex IV - Exemptions from the obligations of Register:	Present
EU EINECS/ELINCS List	231-791-2

16. OTHER INFORMATION

Text of CLP/GHS Classification abbreviations mentioned in Section 3

Reproductive toxicity-Cat.1B; H360D - May damage the unborn child

Germ cell mutagenicity-Cat.1B; H340 - May cause genetic defects

Skin corrosion/irritation-Cat.1A; H314 - Causes severe skin burns and eye damage

Data Sources: Pfizer proprietary drug development information. Publicly available toxicity information.

Reasons for Revision: Updated Section 1 - Identification of the Substance/Preparation and the Company/Undertaking.

Revision date: 19-Jul-2016

Prepared by: Product Stewardship Hazard Communication
Pfizer Global Environment, Health, and Safety Operations

Pfizer Inc believes that the information contained in this Material Safety Data Sheet is accurate, and while it is provided in good faith, it is without warranty of any kind, expressed or implied. If data for a hazard are not included in this document there is no known information at this time.

End of Safety Data Sheet